Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents

Cardiovascular Drugs and Therapy
L H Opie

Abstract

A survey of the pharmacokinetic properties of the three prototypical calcium antagonist agents shows that they have in common a very high rate of hepatic first-pass metabolism with, in the case of verapamil and diltiazem, the formation of an active metabolite that affects the dose during chronic therapy. Therefore, the major factor altering the pharmacokinetic properties and the dose of the drug required is the capacity of the liver to metabolize the drug, which in turn depends on the hepatic blood flow and the activity of the hepatic metabolizing systems. Hence liver disease, a low cardiac output, and coadministration of certain drugs inducing or inhibiting the hepatic enzymes, all indirectly affect the pharmacokinetic properties of the calcium antagonists. There are also other potential drug interactions of a kinetic or dynamic nature that may arise. In general, renal disease has little effect on the pharmacokinetics of calcium antagonists.

References

Sep 1, 1985·Journal of Cardiovascular Pharmacology·S UrienJ P Tillement
Jan 1, 1988·Journal of Cardiovascular Pharmacology·H L ElliottJ K Faulkner
Jan 1, 1988·Clinical Pharmacology and Therapeutics·M A LevineF H Leenen
Jan 1, 1985·Drugs·D Elmfeldt, T Hedner
Jan 1, 1986·European Journal of Clinical Pharmacology·H GhabrialM L Mashford
Dec 12, 1987·Lancet·J van HartenD D Breimer
Dec 1, 1987·British Journal of Clinical Pharmacology·J WebsterH M Towler
Mar 1, 1988·Cardiovascular Drugs and Therapy·J O ParkerV Bernstein
Jun 1, 1988·British Journal of Clinical Pharmacology·J van HartenD D Breimer
Mar 1, 1988·British Journal of Clinical Pharmacology·M ScottT J Fitzsimons
Mar 1, 1988·British Journal of Clinical Pharmacology·D R RobertsonC F George
Jul 9, 1988·BMJ : British Medical Journal·D J MaxwellL D Allan
Jan 1, 1987·European Journal of Drug Metabolism and Pharmacokinetics·R J FrancisV Wright
Aug 1, 1986·British Journal of Clinical Pharmacology·W KirchE E Ohnhaus
Nov 1, 1986·Clinical Pharmacokinetics·H Echizen, M Eichelbaum
Mar 1, 1987·British Journal of Clinical Pharmacology·S R SmithM R Wilkins
Mar 1, 1987·British Journal of Clinical Pharmacology·P G ReidA P Smith
Jan 1, 1987·European Journal of Clinical Pharmacology·P DylewiczE E Ohnhaus
Dec 1, 1987·Clinical Cardiology·T J WalleyD B Barnett
Jan 1, 1986·European Journal of Clinical Pharmacology·B SilkeS H Taylor
Dec 15, 1986·The American Journal of Medicine·R G McAllister
Jan 1, 1987·British Journal of Clinical Pharmacology·F M GengoH Bernhard
Jan 1, 1985·British Journal of Clinical Pharmacology·F ForetteM Guerret
Mar 1, 1985·Journal of the American College of Cardiology·M A FiferW H Barry
Mar 1, 1985·British Journal of Clinical Pharmacology·L M WingK J Lillywhite

❮ Previous
Next ❯

Citations

Jul 29, 1998·Bioorganic & Medicinal Chemistry·P ValentiA Chiarini
Aug 17, 1990·Klinische Wochenschrift·R H SchwingerE Erdmann
Apr 26, 2005·Bioorganic & Medicinal Chemistry·Roberta BudriesiAlberto Chiarini

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.